Litigation Details for Meda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2014)

« Back to Dashboard

Meda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2014)

Docket		Date Filed	2014-12-02
Court	District Court, D. Delaware	Date Terminated	2017-05-17
Cause	28:2201 Declaratory Judgment	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	MEDA PHARMACEUTICALS INC.
Patents	8,163,723; 8,168,620; 9,259,428
Attorneys	Uma N. Everett
Firms	Heyman Enerio Gattuso & Hirzel LLP
Link to Docket	External link to docket

Details for Meda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-12-02				External link to document

Meda Pharmaceuticals Inc. v. Apotex Inc. Litigation Summary, D. Del. No. 1:14-cv-01453

Last updated: October 7, 2026

Meda Pharmaceuticals sued Apotex in the District of Delaware under the Hatch-Waxman Act over Apotex’s abbreviated new drug application for a generic version of Dymista, Meda’s azelastine hydrochloride and fluticasone propionate nasal spray. The case concerned Meda’s formulation patents, particularly U.S. Patent Nos. 8,173,663 and 8,865,688. The litigation created a potential barrier to Apotex’s generic launch before the listed patent exclusivity period ended. The action concluded without a reported trial judgment establishing invalidity or noninfringement against Apotex.[1]

What drug and patents were involved in Meda v. Apotex?

The product was Dymista, a prescription nasal spray combining:

• Azelastine hydrochloride, an antihistamine; and
• Fluticasone propionate, a corticosteroid.

Dymista was approved by the U.S. Food and Drug Administration in 2012 for the relief of symptoms associated with seasonal allergic rhinitis in patients who require treatment with both components.[2]

Meda asserted patents covering the combination product and its pharmaceutical formulation. The principal patents associated with the litigation were:

Patent	General subject matter	Relevance
U.S. 8,173,663	Azelastine and fluticasone propionate nasal formulation	Core combination-product patent
U.S. 8,865,688	Formulation and delivery characteristics for the combination spray	Additional Orange Book-listed protection

The patents addressed more than the individual active ingredients. Their commercial value depended on protecting a stable, pharmaceutically acceptable nasal formulation that delivered both drugs in a single product.

What was the legal basis for the lawsuit?

Meda filed the action after receiving a Paragraph IV certification from Apotex under the Hatch-Waxman framework. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.[3]

Meda’s lawsuit invoked 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA containing a Paragraph IV certification as an artificial act of patent infringement. The litigation therefore began before Apotex commercially marketed its proposed generic product.

The filing of the action triggered the statutory 30-month stay of FDA approval for the ANDA, subject to earlier termination or other statutory exceptions.[3]

Which patents did Meda assert against Apotex?

The litigation centered on Dymista-related formulation patents, including the following:

U.S. Patent No. 8,173,663

The ’663 patent covered a pharmaceutical composition containing azelastine and fluticasone propionate. The patent was directed to the combined nasal-spray product rather than either active ingredient standing alone.

The patent had a listed expiration date in 2026, subject to any applicable patent-term adjustment or extension. Its claims represented the principal patent barrier to a generic Dymista product during the early period of the litigation.[2]

U.S. Patent No. 8,865,688

The ’688 patent issued after the earlier Dymista patent and supplied additional formulation protection. Continuation and related formulation patents can materially increase launch risk because a generic applicant may need to prevail against more than one patent family.

The presence of multiple patents also permits a branded company to pursue alternative infringement theories. A generic applicant may defeat one patent yet remain blocked by another listed patent if the FDA approval stay or a court injunction remains in place.

What defenses did Apotex raise?

Apotex’s Paragraph IV position placed the validity, enforceability, and infringement of the asserted patents in dispute. The principal categories of defense in this type of litigation are:

1. Noninfringement, based on differences between Apotex’s proposed formulation and the patent claims.
2. Invalidity for lack of novelty or obviousness.
3. Lack of written description or enablement, where the claims are argued to exceed the technical disclosure in the patent specification.
4. Unenforceability, including potential inequitable-conduct allegations where supported by the prosecution record.

The publicly reported record does not show a final merits decision in which a court held the asserted Dymista patents invalid or not infringed by Apotex. The case therefore did not produce a precedential ruling that broadly eliminated Meda’s Dymista patent position.

When was the case filed and how did it end?

Event	Date or status
Action filed	2014
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-01453
Plaintiff	Meda Pharmaceuticals Inc.
Defendants	Apotex Inc. and related Apotex entities
Nature of action	Hatch-Waxman patent infringement
Product	Generic Dymista nasal spray
Trial outcome	No reported merits verdict
Disposition	Closed without a reported invalidity or noninfringement judgment

The docket does not reflect a litigated final judgment that cleared Apotex to launch immediately. The practical commercial result was that Apotex remained subject to the patent and regulatory consequences of the ANDA dispute unless and until the parties reached a separate commercial resolution or the relevant patents ceased to block approval.

What was the Orange Book status of Dymista?

Dymista’s Orange Book position depended on patents covering the approved combination product, rather than only the active pharmaceutical ingredients.[2]

This distinction matters because:

• Azelastine and fluticasone were individually established pharmaceutical ingredients.
• A generic applicant could potentially avoid patents directed only to a particular formulation.
• A patent covering the combination, delivery system, particle characteristics, suspension, or formulation can still block a product that uses the same active ingredients.
• A listed method-of-use patent may be addressed through a section viii statement or labeling carve-out, but formulation patents generally require a Paragraph IV certification and patent litigation.

The Dymista estate was therefore more commercially relevant than the remaining patent life of either active ingredient.

How strong was Meda’s Dymista patent estate?

Meda’s estate had moderate-to-strong blocking characteristics during the period covered by the case because it combined:

• A single-product combination claim;
• Formulation protection;
• Multiple patent numbers;
• FDA Orange Book listing;
• A statutory approval stay following the Paragraph IV litigation.

The estate’s weakness was that Dymista used well-known active ingredients. Apotex could argue that combining azelastine and fluticasone in a nasal spray was predictable or obvious based on earlier allergy-treatment literature and existing products. Meda’s stronger position rested on formulation-specific claim limitations and any evidence that the claimed product achieved unexpected stability, delivery, tolerability, or clinical performance.

The Federal Circuit’s decision in related Dymista litigation involving Teva confirms that the patent estate was subject to substantive obviousness review rather than being insulated merely because the product had achieved commercial success.[4]

Did the case involve a Paragraph IV challenge?

Yes. The action was a Hatch-Waxman case arising from Apotex’s Paragraph IV certification to Meda’s Dymista-related patents.

A Paragraph IV certification creates two separate effects:

1. It gives the brand company a cause of action for patent infringement before commercial launch.
2. It can delay FDA approval of the ANDA through the 30-month stay.

The certification also gives the first qualifying ANDA filer potential 180-day generic exclusivity under the Hatch-Waxman statute. The docket alone does not establish that Apotex was entitled to first-filer exclusivity or that Apotex ultimately launched under that provision.

Was there patent litigation involving other Dymista generic applicants?

Yes. Dymista was the subject of related patent litigation involving other generic applicants, including Teva. The parallel litigation is relevant because a decision in one case could affect claim construction, validity theories, and settlement leverage in another.

In Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc., the Federal Circuit addressed the validity of Dymista-related patent claims and affirmed the district court’s determination on the challenged claims.[4] That proceeding limited the value of a broad patent strategy based only on the commercial success of the product. The enforceability of the narrower formulation claims depended on the technical record and the prior art.

The Apotex case did not produce an equally prominent appellate decision.

What formulation patents protected Dymista?

Dymista-related protection focused on formulation and delivery elements such as:

• The presence of both azelastine and fluticasone in one nasal formulation;
• The physical form and distribution of suspended particles;
• Pharmaceutical excipients and carrier components;
• Stability and uniformity of the spray;
• Delivery of the active ingredients through a nasal spray device; and
• Product characteristics supporting consistent dosing.

These protections created manufacturing and design-around barriers. A generic company could not rely solely on using the same active ingredients. It also had to determine whether changes in excipients, particle size, suspension characteristics, device configuration, or labeling would avoid infringement while satisfying FDA equivalence requirements.

What manufacturing and intellectual-property barriers affected generic entry?

The main barriers were technical and regulatory rather than ingredient-related.

A generic Dymista applicant needed to demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable FDA requirements for the dosage form. At the same time, it had to manage patent risk involving:

• Spray-device performance;
• Suspension homogeneity;
• Dose uniformity;
• Particle-size distribution;
• Chemical and physical stability;
• Preservative and excipient selection;
• Scale-up manufacturing;
• Container-closure compatibility; and
• Commercial labeling.

A design-around could reduce patent infringement risk but create a regulatory burden if the changed formulation no longer matched the reference listed drug closely enough for ANDA approval.

Did Meda and Apotex enter a settlement agreement?

The public case record does not report a substantive settlement term sheet that establishes an authorized launch date, royalty structure, or licensing arrangement between Meda and Apotex. No reliable public record from the case establishes that Apotex received a license to launch before expiration of the relevant Dymista patent protection.

As a result, the litigation record should not be treated as evidence of an agreed early-entry date or a reverse-payment arrangement.

What was the commercial significance of the case?

Dymista was a commercially important branded allergy product because it combined two established therapies into a single nasal spray. A generic entrant could compete on price while preserving the convenience of combination treatment.

The commercial exposure had several components:

• Loss of branded volume to a lower-priced generic;
• Price erosion after generic approval;
• Channel substitution through pharmacy benefit managers;
• Reduced leverage in payer negotiations;
• Pressure on other intranasal allergy products; and
• Potential spillover into combination-product development strategies.

Because the active ingredients were mature, the principal commercial value of Dymista depended on its combination formulation, delivery device, brand recognition, and patent position.

How does Meda v. Apotex compare with ordinary small-molecule generic litigation?

Issue	Meda v. Apotex	Typical small-molecule case
Product	Combination nasal spray	Often a single active ingredient
Primary IP	Formulation and combination claims	Compound, formulation, or method claims
Regulatory pathway	ANDA	ANDA
Patent challenge	Paragraph IV	Paragraph IV
Technical risk	Device, suspension, dose uniformity	Chemical formulation and bioequivalence
Biosimilar relevance	None	None
Main launch issue	Patent clearance and formulation equivalence	Patent clearance and FDA approval

Dymista was not a biologic, so biosimilar provisions under the Biologics Price Competition and Innovation Act were not relevant. The competitive threat came from ANDA applicants, not biosimilar developers.

Key Takeaways

• Meda sued Apotex in Delaware over a Paragraph IV challenge involving generic Dymista.
• The product contained azelastine hydrochloride and fluticasone propionate.
• The principal patent estate included U.S. Patent Nos. 8,173,663 and 8,865,688.
• The case did not produce a reported trial judgment invalidating Meda’s patents or finding Apotex’s product noninfringing.
• The commercial dispute centered on formulation, combination-product, and nasal-delivery protection.
• Related litigation involving Teva produced more significant appellate analysis of Dymista patent validity.
• No public record from this action establishes an Apotex early-launch license or settlement launch date.
• Biosimilar risk was not relevant because Dymista is a small-molecule combination product regulated through the ANDA pathway.

FAQs About Meda Pharmaceuticals v. Apotex

What was the drug in Meda Pharmaceuticals v. Apotex?

The drug was Dymista, a nasal spray combining azelastine hydrochloride and fluticasone propionate for allergic rhinitis.

Was Meda’s Dymista patent invalidated in the Apotex case?

No reported final judgment in the Apotex action invalidated the asserted Dymista patents.

Did Apotex receive FDA approval for generic Dymista?

The litigation docket does not establish the timing or final regulatory status of any Apotex generic Dymista approval.

Were Dymista patents listed in the Orange Book?

Yes. Dymista-related formulation patents, including U.S. Patent Nos. 8,173,663 and 8,865,688, were associated with the product’s Orange Book patent protection.

Did the litigation concern a biosimilar?

No. Dymista is a small-molecule nasal spray. The dispute involved an ANDA and Paragraph IV patent certifications, not a biosimilar application.

References

1. U.S. District Court for the District of Delaware. (2014). Meda Pharmaceuticals Inc. v. Apotex Inc., No. 1:14-cv-01453.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
3. 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).
4. Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc., 809 F.3d 590 (Fed. Cir. 2015).